Hancock Mark sold $8.1M of PACS

Hancock Mark (Co Fndr; Exec V Chair) sold 200,000 shares of PACS Group, Inc. (PACS) at an average of $40.38 ($40.33–$41.01, $8.08M total) across 3 trades over 2026-06-25 to 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hancock Mark
Published Jun 26, 2026, 10:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 10:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PACS
Neutral
medium confidence
Mentioned
$PACS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PACSNeutralLow
01

Why it matters

An insider/10% owner sold ~$8.08M of shares across three trades at ~$40.33–$41.01, with a stated pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a fundamental repricing.

03

What to watch

The filing does not state tax/financing needs, and the net effect on float/ownership is not provided beyond post-transaction holdings.

Relevance 5/10Novelty 5/10Timing: filed 2026-06-26 after-hours (SEC Form 4)

Background

The article is an SEC Form 4 insider transaction disclosure for PACS Group, Inc.

Company-level read

Ticker impact

$PACSNeutralMedium confidence
Context

PACS Group insider Hancock Mark sold about 200,000 shares in open-market transactions totaling ~$8.08M under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more sentiment/flow-related than fundamental.

Evidence & confidence

Form 4 shows a pre-arranged 10b5-1 sale by an exec/10% owner, with no accompanying operational or financial guidance changes in the text.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may be routine diversification rather than a bearish signal.

Key entities

  • PACS Group, Inc.

    Company whose insider transaction is disclosed on SEC Form 4.

  • Hancock Mark

    Co-founder; Exec V Chair and 10% owner who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PACSMedAI 8/10

What PACS Group (PACS) Said on Its Q3 Earnings Call

PACS Group reported 196 mature, 90 ramping, and 35 new skilled nursing facilities with occupancy ranging from 76.2% to 93.1%. The company acquired 32 Florida and 10 Texas skilled nursing operations post-quarter. PACS raised its 2026 revenue outlook to $5.95B-$6.05B and adjusted EBITDA to $685M-$695M, citing strength in existing operations and new acquisitions. Operating cash flow was $583.1M for the first nine months of 2026, with $707.4M in available liquidity.

$PACSHighAI 8/10

PACS Group Inc (PACS) (Q3 2026) Earnings Call Highlights: Revenue Tops

PACS Group Inc (NYSE:PACS) reported Q3 2026 revenue growth of 6.4%, with adjusted EBITDA up 33.6% to $175.7M. The company raised full-year guidance, citing strong occupancy and skilled mix improvements. PACS also highlighted a robust acquisition pipeline and integration plans for 31 Eduro facilities. Challenges include lower metrics at newly acquired facilities and ongoing government investigations.

$PACSHigh

Why is PACS stock surging today?

PACS Group Inc (PACS) stock rose 6.0% in after-hours trading after beating Q3 2026 earnings and revenue estimates. The company also raised its full-year 2026 Adjusted EBITDA and revenue guidance. Analysts maintain a 'Moderate Buy' rating with an average price target of $58.80. The surge was driven by company-specific news.